binge eating disorder glp 1 GLP-1s & 💊, Eating disorders, including binge eating disorder, are a contraindication for GLP-1 medications. Yet many people are still accessing them privately., During eating-disorder GLP-1 Agonist for Binge Eating

Choose your injection site Three areas of the body work well for subcutaneous GLP-1 injections

The effect of levocarnitine for plasmatic matrix metalloproteinases (MMPS) on acute cerebral infarct patients

MGF is actually a splice variant of the IGF gene itself

Here's what could derail the thesis: Regulatory & Pricing Pressure Government price controls on GLP-1 drugs (Trump administration deal includes price cuts) Medicare/Medicaid coverage expansion requires discounting International pricing pressures as volumes increase Competition Intensifying Novo Nordisk fighting back with oral GLP-1 programs Amgen, Pfizer, and others entering the space Compounding pharmacies eating market share during supply shortages Operational Challenges Manufacturing constraints still limiting supply in some markets CVS formulary changes disrupted Zepbound access temporarily Volume growth partially offset by 10% lower realized prices in Q3 Valuation Risk At ~$930B market cap, expectations are sky-high Any guidance miss or pipeline disappointment will be punished severely Forward P/E of ~42 leaves little room for error Pipeline Execution Orforglipron approval timing uncertain Alzheimer's market adoption slower than hoped Clinical trial failures in crowded pipeline Smart investors acknowledge risks while staying focused on the long-term thesis